The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Abstract
Stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among stimulants are hindered by the absence of direct comparative trials. The goal of this work was to compare the efficacy of methylphenidate and amfetamine formulations through a meta-analysis of double-blind placebo-controlled trials. We analyzed recent published literature on the stimulant therapy of ADHD to describe the variability of drug-placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in children and adolescents published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-three trials met criteria and were included in this meta-analysis. These trials studied 11 drugs using 19 different outcome measures of hyperactive, inattentive, or impulsive behavior. We found significant differences between amfetamine and methylphenidate products, even after correcting for study design features that might have confounded the results. Our analyses indicate that effect sizes for amfetamine products are significantly, albeit moderately, greater than those for methylphenidate. We found that most measures of effect from all studies were statistically significant. Our findings suggest that amfetamine products may be moderately more efficacious than methylphenidate products, even after controlling for potentially confounding…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses have demonstrated that stimulant and non-stimulant medications for ADHD effectively reduce ADHD symptoms inchildren and adults 142,143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“some patients preferentially respond to and tolerate one or the other 143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“Although the efficacy of both classes of stimulants is similar”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“It has been speculated that the moderately greater efficacy of AMP-based agents compared with MPH-based agents in ADHD may be related to differences in their molecular actions (33), but to date there is no conclusive clinical evidence to support this speculation.”
In the citing paper
“It is noteworthy that medications for ADHD operate by altering the availability of NE and DA at cortical sites (Faraone and Buitelaar, 2010),”
From Is autonomic nervous system function atypical in Attention Deficit Hyperactivity Disorder (ADHD)? A systematic review of the evidence (2020) · cites this paper as Faraone and Buitelaar, 2010
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Methods of Meta-Analysis: Correcting Error and Bias in Research Findings
Schmidt, F. L., & Hunter, J. E. (2015) · doi:10.4135/9781483398105 · Cited by 5,542
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Research works printed but not linked: 1
- Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113
Cited by
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Self-citationAttention deficit hyperactivity disorder
Thapar, A., & Cooper, M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00238-x · Cited by 1,043
Attention-deficit hyperactivity disorder
Posner, J., Polanczyk, G. V., & Sonuga-Barke, E. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33004-1 · Cited by 835
Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan
Franke, B., Michelini, G., Asherson, P., Banaschewski, T., Bilbow, A., Buitelaar, J. K., Cormand, B., Faraone, S. V., Ginsberg, Y., Haavik, J., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.08.001 · Cited by 643
Self-citationFaraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“AMP and MPH have been shown to exhibit comparable efficacy in 2 meta-analyses (Faraone and Glatt, 2010; Catala-Lopez et al., 2017), with other analyses reporting that AMP has moderately greater effects than MPH (Faraone and Buitelaar, 2010; Joseph et al., 2017; Stuhec et al., 2015).”
Self-citationAmphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
“However, a meta-analysis by Faraone and Buitelaar (2010) did show moderately greater efficacy for amphetamine medications.”
BackgroundLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Antshel, K. M., & Russo, N. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1020-5 · Cited by 450
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
“Methylphenidate is generally preferred over amphetamine despite some reports that amphetamine possesses slightly better efficacy.(89) For example, because of its slower uptake and clearance,(90) it is much less likely to produce dependence and physical harm to the patient as compared with amphetamine.”
BackgroundEvaluation of neurofeedback in ADHD: The long and winding road
Arns, M., Heinrich, H., & Strehl, U. (2014) · Biological Psychology · doi:10.1016/j.biopsycho.2013.11.013 · Cited by 404
“In Holtmann et al. (2009), where an inhibitionrelated effect of reduced impulsivity errors for neurofeedback was obtained, the neurofeedback training consisted of 20 training sessions, which is generally considered a low number of sessions, known to have smaller effects (Arns et al.”
BackgroundSustained effects of neurofeedback in ADHD: a systematic review and meta-analysis
Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & K. Loo, S. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1121-4 · Cited by 361
“Medication treatments have large effect size in the acute treatment of ADHD [2] and, when combined with psychosocial treatments, large effects up to 2 years of treatment were observed [3, 4].”
BackgroundCortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Graham, J., Taylor, E., Sergeant, J., et al. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12036 · Cited by 336
“A large body of empirical research has consistently demonstrated the efficacy of ADHD drugs over the short to intermediate term (Faraone & Buitelaar, 2010; Faraone & Glatt, 2010).”
BackgroundSelf-citationBolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
“77 for methylphenidate (Faraone and Buitelaar, 2010).”
Coghill, D. R., Seth, S., Pedroso, S., Usala, T., Currie, J., & Gagliano, A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.005 · Cited by 271
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Krueger, R. F., Hobbs, K. A., Conway, C. C., Dick, D. M., Dretsch, M. N., Eaton, N. R., Forbes, M. K., Forbush, K. T., Keyes, K. M., Latzman, R. D., et al. (2021) · World Psychiatry · doi:10.1002/wps.20844 · Cited by 262
An update on the comorbidity of ADHD and ASD: a focus on clinical management
Antshel, K. M., Zhang-James, Y., Wagner, K. E., Ledesma, A., & Faraone, S. V. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1146591 · Cited by 262
Self-citationNigg, J. T., Lewis, K., Edinger, T., & Falk, M. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.10.015 · Cited by 260
Molina, B. S. G., Hinshaw, S. P., Eugene Arnold, L., Swanson, J. M., Pelham, W. E., Hechtman, L., Hoza, B., Epstein, J. N., Wigal, T., Abikoff, H. B., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.12.014 · Cited by 246
“These medications reliably decrease ADHD symptoms for more than 80% of diagnosed children, sometimes dramatically.(7,8) To the extent that symptoms of ADHD contribute to addiction vulnerability, treatment with stimulant medication should theoretically decrease risk.”
BackgroundAnnual Research Review: Optimal outcomes of child and adolescent mental illness
Costello, E. J., & Maughan, B. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12371 · Cited by 204
“In the short term, pharmacological treatments can be extremely effective, with reported effect sizes of .7 and higher (Faraone & Buitelaar, 2010).”
BackgroundNeurofeedback as a Treatment Intervention in ADHD: Current Evidence and Practice
Enriquez-Geppert, S., Smit, D., Pimenta, M. G., & Arns, M. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1021-4 · Cited by 194
ADHD and Smoking: From Genes to Brain to Behavior
McClernon, F. J., & Kollins, S. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.016 · Cited by 188
Oxidative Stress and ADHD: A Meta-Analysis
Joseph, N., Zhang-James, Y., Perl, A., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054713510354 · Cited by 203
“Thus, it is not surprising to see the “paradoxical effect” of stimulant treatment, which causes oxidative stress (El-Tawil, Abou-Hadeed, El-Bab, & Shalaby, 2011; Martins et al., 2006) but is also neuroprotective (Volz, 2008) and is an effective treatment for ADHD (Faraone & Buitelaar, 2010).”
BackgroundSelf-citationFredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173
“If the effect is mediated by symptom reduction, one possibility may be that the efficacy of stimulants seems to be higher for children than for adults, as seen if one compares medication effect sizes reported from meta-analyses of youth (Faraone and Buitelaar, 2010) and adults (Faraone and Glatt, 2010).”
BackgroundResultSelf-citationRuiz-Goikoetxea, M., Cortese, S., Aznarez-Sanado, M., Magallón, S., Alvarez Zallo, N., Luis, E. O., de Castro-Manglano, P., Soutullo, C., & Arrondo, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.007 · Cited by 175
“…from a large body of evidence showing beneficial effects of ADHD medications not only in the short term, for ADHD core symptoms (Faraone and Buitelaar, 2010), but also for neuropsychological dysfunctions (Coghill et al., 2014) and for other very relevant outcomes, such as criminal acts…”
BackgroundPsychosocial Interventions in Attention Deficit Hyperactivity Disorder
Antshel, K. M., & Barkley, R. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.11.005 · Cited by 172
Bellato, A., Arora, I., Hollis, C., & Groom, M. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.001 · Cited by 179
Attention-Deficit/Hyperactivity Disorder
Banaschewski, T., Becker, K., Döpfner, M., Holtmann, M. H., Rösler, M., & Romanos, M. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0149 · Cited by 314
Self-regulation in ADHD: the role of error processing
Shiels, K., & Hawk, L. W. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.06.010 · Cited by 189
Hirota, T., Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.009 · Cited by 161
Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
Spencer, T. J., Brown, A., Seidman, L. J., Valera, E. M., Makris, N., Lomedico, A., Faraone, S. V., & Biederman, J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08287 · Cited by 139
Self-citationHodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0286-5 · Cited by 147
Pelsser, L. M., Frankena, K., Toorman, J., & Rodrigues Pereira, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169277 · Cited by 145
Working memory training in young children with ADHD : a randomized placebo‐controlled trial
van Dongen‐Boomsma, M., Vollebregt, M. A., Buitelaar, J. K., & Slaats‐Willemse, D. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12218 · Cited by 142
Self-citationThe Effects of QEEG-Informed Neurofeedback in ADHD: An Open-Label Pilot Study
Arns, M., Drinkenburg, W. H. I. M., & Kenemans, J. L. (2012) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-012-9191-4 · Cited by 154
“In comparison, a recently conducted metaanalysis on the effects of stimulant medication in ADHD found an ES of 0.84 for Ritalin on ATT (Faraone and Buitelaar 2009).”
InfluentialReichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134
“…treating ADHD in children with PDD (ES = .67), however it is slightly lower than estimates from studies examining methylphenidate for ADHD symptoms in typically developing children with ADHD alone (e.g., ES = .78; 95 % CI .64–.91; (Schachter et al. 2001); ES = 1.03; (Faraone and Buitelaar 2010)).”
ResultInfluentialSaylor, K. E., & Amann, B. H. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0126 · Cited by 159
Swart, J. C., Froböse, M. I., Cook, J. L., Geurts, D. E. M., Frank, M. J., Cools, R., & den Ouden, H. E. M. (2017) · eLife · doi:10.7554/elife.22169 · Cited by 149
“…of neuropsychiatric disorders, such as attention deficit hyperactivity disorder, Parkinson’s disease, and addiction (Dagher and Robbins, 2009; Prince, 2008; Skolnick, 2005), and many of those deficits can be treated with catecholaminergic drugs (Faraone and Buitelaar, 2010; Wigal et al., 2011).”
BackgroundCoghill, D., Banaschewski, T., Zuddas, A., Pelaz, A., Gagliano, A., & Döepfner, M. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-237 · Cited by 126
“…et al., 2006 [55] Equasym XLW; Ritalin LAW; n = 29 articles Effect size expressed as SMD ConcertaW; DaytranaW Children and adolescents Faraone and Buitelaar, 2010 [56] Equasym XLW; Ritalin LAW; n = 23 articles Effect size expressed as SMD ConcertaW; DaytranaW Children and…”
van Lieshout, M., Luman, M., Twisk, J. W. R., van Ewijk, H., Groenman, A. P., Thissen, A. J. A. M., Faraone, S. V., Heslenfeld, D. J., Hartman, C. A., Hoekstra, P. J., et al. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-016-0820-y · Cited by 138
“Another important caveat is that not many studies took pharmacological treatment into account, which may have a significant impact on ADHD outcomes [15].”
BackgroundSelf-citationHow effective are common medications: a perspective based on meta-analyses of major drugs
Leucht, S., Helfer, B., Gartlehner, G., & Davis, J. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0494-1 · Cited by 120
“with red color are outcomes that can be objectively measured and are patient-oriented [8–12, 15–18, 23–32].”
BackgroundSchuck, S. E. B., Emmerson, N. A., Fine, A. H., & Lakes, K. D. (2015) · Journal of Attention Disorders · doi:10.1177/1087054713502080 · Cited by 114
Stevenson, J., Buitelaar, J., Cortese, S., Ferrin, M., Konofal, E., Lecendreux, M., Simonoff, E., Wong, I. C. K., & Sonuga‐Barke, E. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12215 · Cited by 106
Self-citationArns, M., & Kenemans, J. L. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.006 · Cited by 132
Cooper, R. E., Tye, C., Kuntsi, J., Vassos, E., & Asherson, P. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115587958 · Cited by 126
Neurofeedback in children with ADHD: validation and challenges
Gevensleben, H., Rothenberger, A., Moll, G. H., & Heinrich, H. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.22 · Cited by 116
Carucci, S., Balia, C., Gagliano, A., Lampis, A., Buitelaar, J. K., Danckaerts, M., Dittmann, R., Garas, P., Hollis, C. P., Inglis, S. K., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.031 · Cited by 135
Self-citationKaranges, E. A., Stephenson, C. P., & McGregor, I. S. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414538675 · Cited by 106
“Australian & New Zealand Journal of Psychiatry, 48(10) educational and social outcomes (Faraone and Buitelaar, 2010).”
BackgroundArns, M., Clark, C. R., Trullinger, M., DeBeus, R. J., Mack, M. D., & Aniftos, M. (2020) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-020-09455-2 · Cited by 116
van de Loo-Neus, G. H. H., Rommelse, N., & Buitelaar, J. K. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.03.008 · Cited by 98
“Although head-to-head clinical trials provide the best data to draw conclusions about differences in efficacy between different medications, meta-analyses may serve this purpose as well (Faraone, 2009; Faraone and Buitelaar, 2010).”
BackgroundSelf-citationComputer-based Cognitive Training for ADHD
Sonuga-Barke, E., Brandeis, D., Holtmann, M., & Cortese, S. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.05.009 · Cited by 92
Bralten, J., Franke, B., Waldman, I., Rommelse, N., Hartman, C., Asherson, P., Banaschewski, T., Ebstein, R. P., Gill, M., Miranda, A., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.08.020 · Cited by 93
Self-citationStein, M. A., Waldman, I. D., Charney, E., Aryal, S., Sable, C., Gruber, R., & Newcorn, J. H. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0018 · Cited by 101
“An important context for this study comparing the effects of ER formulations of MPH and AMP is the current national interest in Comparative Effectiveness Research (CER) (Clancy 2009).”
InfluentialSagvolden, T., & Johansen, E. B. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_126 · Cited by 103
“However, a positive response to medication is not a defining feature of ADHD: up to one in five children diagnosed with ADHD will similarly not respond positively (Faraone and Buitelaar 2010).”
BackgroundInterventions for Executive Function Deficits in Children and Adolescents
Riccio, C. A., & Gomes, H. (2013) · Applied Neuropsychology Child · doi:10.1080/21622965.2013.748383 · Cited by 110
“Recent meta-analyses (e.g., Faraone, Biederman, Spencer, & Aleardi, 2006; Faraone & Buitelaar, 2010) consistently yielded mean effect sizes in the medium-to-high range for efficacy of stimulant medications for individuals with ADHD.”
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD
Myer, N. M., Boland, J. R., & Faraone, S. V. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.234 · Cited by 91
Self-citationDopamine and the motivation of cognitive control
Cools, R., Froböse, M. I., Aarts, E., & Hofmans, L. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804281-6.00007-0 · Cited by 103
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0166-2 · Cited by 89
“In a series of randomized, controlled trials, effect sizes for LDX have been shown to be greater than those for MPH-based stimulants in the treatment of children and adolescents with ADHD [8], and a post hoc analysis of data from a randomized, placeboand active-controlled phase III clinical trial showed that improveme…”
BackgroundQuantitative EEG and Neurofeedback in Children and Adolescents
Simkin, D. R., Thatcher, R. W., & Lubar, J. F. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.03.001 · Cited by 119
Vollebregt, M. A., van Dongen‐Boomsma, M., Buitelaar, J. K., & Slaats-Willemse, D. I. E. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12143 · Cited by 91
“Double blind, placebo-controlled trials have shown an effect size of 0.6 or more for the first-line treatment of ADHD with medication (Faraone & Buitelaar, 2010; Michelson et al., 2002).”
BackgroundInfluentialSelf-citationChronis-Tuscano, A. M., Wang, C. H., Woods, K., Strickland, J., & Stein, M. A. (2016) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-016-0238-5 · Cited by 114
“Stimulant medications are the most commonly used, evidence-based intervention for child ADHD (Faraone and Buitelaar 2010).”
BackgroundNeurofeedback in ADHD: Further Pieces of the Puzzle
Gevensleben, H., Kleemeyer, M. M., Rothenberger, L. G., Studer, P., Flaig-Röhr, A., Moll, G. H., Rothenberger, A., & Heinrich, H. (2013) · Brain Topography · doi:10.1007/s10548-013-0285-y · Cited by 95
Tamminga, H. G. H., Reneman, L., Huizenga, H. M., & Geurts, H. M. (2016) · Psychological Medicine · doi:10.1017/s0033291716000350 · Cited by 82
“…studies have suggested an age-dependency of MPH effects when comparing young children with older children and adolescents (Hanisch et al. 2004; Faraone & Buitelaar, 2010; Chamberlain et al. 2011), the age-dependency across the life span (i.e. including adulthood) is more apparent from animal…”
ResultInfluentialLearning curves of theta/beta neurofeedback in children with ADHD
Janssen, T. W. P., Bink, M., Weeda, W. D., Geladé, K., van Mourik, R., Maras, A., & Oosterlaan, J. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-016-0920-8 · Cited by 85
Matthijssen, A. M., Dietrich, A., Bierens, M., Deters, R. K., van de Loo-Neus, G. H. H., van den Hoofdakker, B. J., Buitelaar, J. K., & Hoekstra, P. J. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18111296 · Cited by 90
Self-citationPharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents
Childress, A. C., & Berry, S. A. (2012) · Drugs · doi:10.2165/11599580-000000000-00000 · Cited by 77
“However, data suggest that amphetamines may be moderately more effective.([32]) The AACAP advises that extended-release stimulant preparations are appropriate for initial treatment.”
BackgroundPfiffner, L. J., Rooney, M. E., Haack, L. M., Villodas, M. T., Delucchi, K., & McBurnett, K. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.05.023 · Cited by 93
Use of Mental Health Services by Children Ages Six to 11 With Emotional or Behavioral Difficulties
Simon, A. E., Pastor, P. N., Reuben, C. A., Huang, L. N., & Goldstrom, I. D. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400342 · Cited by 82
“Clinical studies have established the efficacy and safety of psychotropic medications for the treatment of some childhood mental disorders (10), including ADHD (11,12), and guidelines for their use have been developed (13).”
BackgroundInfluentialChildress, A. C., Komolova, M., & Sallee, F. R. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1675636 · Cited by 94
“While the moderately greater efficacy of AMP versus MPH in patients with ADHD may be related to their distinct mechanisms of action, there is no conclusive evidence or guidelines to support the use of one stimulant type over another in specific patient populations [9,16,17].”
BackgroundWorking Memory Capacity Predicts Effects of Methylphenidate on Reversal Learning
van der Schaaf, M. E., Fallon, S. J., ter Huurne, N., Buitelaar, J. K., & Cools, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.100 · Cited by 78
“In the clinical context, MPH decreases symptoms of inattention and hyperactivity (Faraone and Buitelaar, 2010) and may improve attentional and academic performance (Marcus and Durkin, 2011; Wigal et al, 2011).”
BackgroundSelf-citationBaijot, S., Slama, H., Söderlund, G. B. W., Dan, B., Deltenre, P., Colin, C., & Deconinck, N. (2016) · Behavioral and Brain Functions · doi:10.1186/s12993-016-0095-y · Cited by 89
Geladé, K., Bink, M., Janssen, T. W. P., van Mourik, R., Maras, A., & Oosterlaan, J. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-016-0902-x · Cited by 90
Heidbreder, R. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-015-0171-4 · Cited by 89
Current Pharmacological Treatments for ADHD
Groom, M. J., & Cortese, S. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_330 · Cited by 76
Ketogenic therapy in neurodegenerative and psychiatric disorders: From mice to men
Kraeuter, A.-K., Phillips, R., & Sarnyai, Z. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109913 · Cited by 71
Maia, C. R. M., Cortese, S., Caye, A., Deakin, T. K., Polanczyk, G. V., Polanczyk, C. A., & Rohde, L. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054714559643 · Cited by 65
“However, we noted that a meta-analysis on stimulants for children (Faraone & Buitelaar, 2010) demonstrated no significant difference with or without the LOCF approach.”
BackgroundResultUsing the Diffusion Model to Explain Cognitive Deficits in Attention Deficit Hyperactivity Disorder
Huang‐Pollock, C. L., Ratcliff, R., McKoon, G., Shapiro, Z. R., Weigard, A., & Galloway-Long, H. (2016) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-016-0151-y · Cited by 78
“In comparison, methylphenidate’s mechanism of action is presumed to act primarily on the dopamine system (Faraone and Buitelaar 2010).”
Biederman, J., Fried, R. S., DiSalvo, M., Storch, B., Pulli, A., Woodworth, K. Y., Biederman, I., Faraone, S. V., & Perlis, R. H. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800515 · Cited by 72
Self-citationSallee, F. R., Connor, D. F., & Newcorn, J. H. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0028 · Cited by 75
“Effect sizes have been proposed as a means of comparing results across studies, despite differences in measures and study design (Faraone and Buitelaar 2010).”
Janssen, T. W. P., Bink, M., Geladé, K., van Mourik, R., Maras, A., & Oosterlaan, J. (2016) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12517 · Cited by 81
“Although stimulant medication is effective in short-term symptom reduction (Faraone & Buitelaar, 2010), approximately 30% do not respond favourably (Spencer et al., 1996) or experience adverse effects (Graham & Coghill, 2008).”
Moriyama, T. S., Polanczyk, G. V., Terzi, F. S., Faria, K. V. M., & Rohde, L. A. (2013) · CNS Spectrums · doi:10.1017/s109285291300031x · Cited by 79
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
“A guide to treatment of adults with ADHD.”
ResultInfluentialBedard, A., Stein, M. A., Halperin, J. M., Krone, B., Rajwan, E., & Newcorn, J. H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12272 · Cited by 74
“Further, the effect sizes for CPT-measured cognitive improvements with MPH here are in agreement with previous reviews that demonstrate smaller effects on cognitive function than on behavior (Faraone & Buitelaar, 2010; Pietrzak et al., 2006).”
ResultBarragán, E., Breuer, D., & Döpfner, M. (2014) · Journal of Attention Disorders · doi:10.1177/1087054713518239 · Cited by 71
“Faraone and Buitelaar (2010), in their meta-analysis of randomized controlled trials using parent ratings, found a standardized mean difference (SMD, that is, effect size) of 0.73 on ADHD total scores for stimulant treatment.”
BackgroundInfluentialDevelopments and challenges in the diagnosis and treatment of ADHD
Dias, T. G. C., Kieling, C., Graeff-Martins, A. S., Moriyama, T. S., Rohde, L. A., & Polanczyk, G. V. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-s103 · Cited by 62
Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children
Holmes, G. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00428-w · Cited by 67
Nagashima, M., Monden, Y., Dan, I., Dan, H., Tsuzuki, D., Mizutani, T., Kyutoku, Y., Gunji, Y., Hirano, D., Taniguchi, T., et al. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.09.001 · Cited by 69
“…drug, atomoxetine (ATX) aswell as the stimulant drug, methylphenidate (MPH) have been recommended as primary medications for the improvement of executive function in ADHD patients (Cubillo et al., 2014; Faraone and Buitelaar, 2010; Faraone et al., 2007; Newcorn et al., 2008; Sallee et al., 2009).”
Treuer, T., Gau, S. S.-F., Méndez, L., Montgomery, W., Monk, J. A., Altin, M., Wu, S., Lin, C. C. H., & Dueñas, H. J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0093 · Cited by 58
“Both stimulants and atomoxetine as monotherapy are effective for the treatment of ADHD (Faraone et al. 2006; Cheng et al. 2007; Mészáros et al. 2009; Faraone and Buitelaar 2010; Hanwella et al. 2011), and combination therapy may be more effective than stimulants as shown in studies of stimulants coadministered with cl…”
InfluentialJanssen, T. W. P., Bink, M., Geladé, K., van Mourik, R., Maras, A., & Oosterlaan, J. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0144 · Cited by 58
“Stimulant medication is the first-choice treatment for ADHD and is effective in short-term symptom reduction (Faraone and Buitelaar 2010).”
Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00617 · Cited by 64
Jans, T., Jacob, C., Warnke, A., Zwanzger, U., Groß‐Lesch, S., Matthies, S., Borel, P., Hennighausen, K., Haack‐Dees, B., Rösler, M., et al. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12443 · Cited by 64
A Position Paper on Neurofeedback for the Treatment of ADHD
Sherlin, L. H., Arns, M., Lubar, J. F., & Sokhadze, E. M. (2010) · Journal of Neurotherapy · doi:10.1080/10874201003773880 · Cited by 60
“Recently, a meta-analysis was conducted on two types of stimulant medication in the treatment of ADHD by Faraone and Buitelaar (2009).”
MethodGuanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Huß, M., Chen, W., & Ludolph, A. G. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0336-0 · Cited by 67
“5) [15, 16], and MPH is generally recommended in Europe as the first choice medication for children/adolescents with ADHD [2, 13].”
BackgroundDose, C., Hautmann, C., Bürger, M., Schuermann, S., Woitecki, K., & Döepfner, M. (2016) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12661 · Cited by 58
Zhang, J., Díaz-Román, A., & Cortese, S. (2018) · Evidence Based Mental Health · doi:10.1136/ebmental-2018-300015 · Cited by 55
Ruggiero, S., Clavenna, A., Reale, L., Capuano, A., Rossi, F., & Bonati, M. R. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.001 · Cited by 58
“2) in reducing ADHD symptoms.(Faraone and Buitelaar, 2010) It is actually difficult to assess the efficacy of different medications in the absence of direct comparisons within the same study.”
BackgroundMeta-Analysis: Parental Interventions for Preschool ADHD
Mulqueen, J. M., Bartley, C. A., & Bloch, M. H. (2013) · Journal of Attention Disorders · doi:10.1177/1087054713504135 · Cited by 68
“Psychostimulant medications have been well researched for school-aged children with ADHD and have demonstrated to be significantly more effective than behavioral treatments over the short term (Faraone & Buitelaar, 2010).”
BackgroundWhite noise as a possible therapeutic option for children with ADHD
Pickens, T. A., Khan, S. P., & Berlau, D. J. (2018) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.11.012 · Cited by 58
Lobato, C. T., Arias, L. H. M., Sáinz-Gil, M., Valdivieso, I. S., Ortega, P. G., Velasco, V., Bulnes, N. J., Escudero, A., Velasco, A., & Carvajal, A. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2348 · Cited by 55
Metadata
- Authors
- Faraone, S. V., & Buitelaar, J.
- Affiliations
- SUNY Upstate Medical University (US)
- Radboud University Nijmegen (NL)
- Corresponding author
- Faraone, Stephen V.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-09-10
- Volume
- 19
- Issue
- 4
- Pages
- 353-364
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2099805984
- Cited by
- 485
- References
- 54
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 14 · 2023: 20 · 2022: 22 · 2021: 21 · 2020: 35 · 2019: 36 · 2018: 29 · 2017: 31 · 2016: 42 · 2015: 53 · 2014: 47 · 2013: 40 · 2012: 26
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- attention deficit hyperactivity disorder, stimulant medication, methylphenidate, amphetamine, drug efficacy comparison, placebo effect, hyperactivity, inattention, impulsivity, children and adolescents, dopamine signaling
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.